775 results about "Bacillus strain" patented technology

An isolated Bacillus strain LSSAO1 is provided. When fed to a bird, this and other Bacillus strains described herein provide benefits to the birds. For example, administration of the one or more Bacillus strain can increase low G+C, gram positive bacteria in the gastrointestinal flora of the bird. These type of bacteria are increased by antibiotics and include beneficial Clostridium. Administration of the one or more Bacillus strain can also inhibit pathogen in the bird, such as E. coli, Salmonella, and Clostridium. These benefits can enhance feed conversion in poultry. Useful combinations of Bacillus strains and methods of using one or more Bacillus strain are also provided.

The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The present invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria-mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.

Disclosed are methods of administering at least two Bacillus strains to a pig, such as female breeding stock, nursery pigs, or other pigs. The Bacillus strains inhibit Clostridium in litters borne to the pig. The Bacillus strains also are useful when administered to herds lacking symptoms of Clostridium infection. Administration of the Bacillus strains improves performance of female breeding stock and in piglets borne by the female breeding stock.

The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The present invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria-mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.

A non-sporulating Bacillus subtilis strain, a method for preparing it and its use as a production organism. A method for preparing a biologically prepared product with the non-sporulating bacterium is also disclosed.

Belonging to the field of environmental microorganism application, the invention discloses a Bacillus subtilis strain and application thereof. The strain is named as Bacillus subtilis CM-A12, is currently preserved in China Center For Type Culture Collection (called CCTCC for short) with a preservation number of CCTCC NO:M 2015688, and the preservation date is November 23, 2015. The Bacillus subtilis strain provided by the invention has the advantages of simple cultivation condition, high temperature resistance, acid and alkali resistance, and high salinity resistance, can secrete protease, amylase and cellulase, and can effectively improve water quality and reduce COD and ammonia nitrogen in water.

A composition is provided that includes Bacillus subtilis 2084 (NRRL B-50013) or a strain having all of the identifying characteristics of the Bacillus subtilis 2084 (NRRL B-50013), B. subtilis 27 (NRRL B-50105) or a strain having all of the identifying characteristics of the B. subtilis 27 (NRRL B-50105), and B. licheniformis 21 (NRRL B-50134) or a strain having all of the identifying characteristics of the B. licheniformis 21 (NRRL B-50134). Animal bedding that includes the Bacillus strains is also provided, as well as a method of making the animal bedding. Also provided are methods of controlling odors from animal waste. A method of making a composition including the Bacillus strains is also provided.

Bacillus strains that inhibit pathogenic swine E. coli and / or improve performance are provided. Inhibition of pathogenic swine E. coli decreases E. coli disease. At least one strain enhanced swine performance by improving average daily gain, feed efficiency, and feed intake. Preferred Bacillus strains are of species that are included on the GRAS list. Bacillus species are sporeformers and therefore are highly stable and can be fed to swine.

The invention discloses a bacillus velezensis ZJ20 strain and liquid preparations thereof. The bacillus velezensis ZJ20 strain is preserved in China general microbiological culture collection center in Chaoyang district, Beijing, China under the number of CGMCC NO.5995 on April 13 2012. A microbial biocontrol agent, namely the novel bacillus velezensis ZJ20 strain, prepared by screening has endospores with high stress resistance and long shelf life, is highly environmentally adaptive and can be produced into commercial biological agents. Metabolites of the bacillus velezensis ZJ20 strain have high bactericidal power, have high colonization ability and fast speed on plants, and can occupy the surface of hybrid bamboo effectively to prevent dieback. Antibacterial protein (chitin with protein) produced by the strain is antibacterial, can promote growth of hybrid bamboo and various types of bamboo branches and leaves, and have a novel effect of recovering posterior production capacity.

The invention discloses a bacillus and application thereof, and belongs to the field of biological control. A bacillus strain is bacillus methylotrophicus C1, and a preservation number of the bacillus strain is GDMCC No.60046. The application includes that the bacillus can be used as a biological control strain to be applied to antagonistic crop pathogenic bacteria; the bacillus can be used as a lipopeptide and / or protein fermentation strain for inhibiting crop pathogenic bacteria; the bacillus can be used as a growth promotion strain to be applied to promoting growth of crops; the bacillus can be used as a fermentation strain for auxin. The bacillus and the application have the advantages that the strain has broad-spectrum antibacterial activity; lipopeptide substances with effects of inhibiting fusarium graminearum cannot be generated, but proteins with effects of inhibiting the fusarium graminearum can be generated; effects of promoting growth of corn can be realized by the strain C1, the root lengths and the stalk lengths of the corn of experiment groups are 3.15 and 3.05 times the root lengths and the stalk lengths of contrast groups respectively as compared with contrast, the root, stalk and seed weights of the corn of the experiment groups are 5.02, 4.33 and 1.4 times the root, stalk and seed weights of the contrast groups, and only little auxin can be generated by the strain C1.

The invention discloses application of fermentation liquor of bacillus subtilis (CICC No. 10321) in inhibition of growth of penicillium and aspergillus niger. The bacillus subtilis (CICC No. 10321) plays a role in inhibiting penicillium and aspergillus niger (the penicillium and aspergillus niger inhibiting circle is greater than 20 cm), the inhibition effect is good, and the duration is long. The bacillus subtilis is simple in culture, short in cycle and low in cost, is suitable for serving as a mold inhibitor and is used for inhibiting the growth of penicillium and aspergillus niger in easily-mildewed goods, such as feed and the like, and the residues of mycotoxins in animal foods are reduced effectively.